Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment

Top 10 Pharma Drug Discovery Delivery capital raises and investors in the U.S. - november 16th - december 31st, 2025. Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me. * Surmodics, performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays, was acquired by GTCR through a $626.85 million public-to-private LBO. * Aeovian Pharmaceuticals, biotechnology therapies that address inflammatory and degenerative diseases, raised $55 million of Series B venture funding in a deal led by CTI Life Sciences Fund and Luma Group. * Imbria Pharmaceuticals, novel therapies for patients with life-altering cardiometabolic disorders, raised $66.70 million of Series B venture funding in a deal led by Deep Track Capital. * Mend, clinical nutritional products that assist people in healing and living a quality life, raised $20.45 million of Series A venture funding led by S2G Investments. * ProLynx, ultra-long-acting medicines for obesity and other metabolic diseases, raised $70 million through a combination of Series A-1, Series A-2, and Series A-3 venture funding in a deal led by OrbiMed and 5AM Ventures. * Vitrivax, thermostable vaccine formulations that eliminate barriers to global vaccination, raised $29.43 million through a combination of Series B-1 and Series B-2 venture funding in a deal led by RA Capital Management and Adjuvant Capital. * Addition Therapeutics, biotech and pharmaceutical research company that transforms genetic medicine, raised $106.5 million of venture funding from Abingworth, SR One Capital Management and Osage University Partners. * Quarry Thera, proximity-driven therapeutics that overcomes limitations in conventional drug modalities, raised $32 million of Series A venture funding from Eli Lilly, Yosemite and Canaan Partners. * Solve Therapeutics, drug development platform that develops novel antibody-drug conjugates, raised $321 million of Series A venture funding in a deal led by Yosemite. * Juniper Biosciences, therapeutic and diagnostic agents intended for precision healthcare and disease management purposes, raised $40 million of seed funding in a deal led by Nova Capital. Diana ruddy. Managing director. Please contact me if you have any questions or would like to discuss your capital raise:

Using a novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can be administered monthly or quarterly.